id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-2225-0006,FDA,FDA-2022-E-2225,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2025-01-16T05:00:00Z,2025,1,2025-01-16T05:00:00Z,,2025-01-16T21:19:21Z,,0,0,09000064868c4b44
FDA-2022-E-2225-0005,FDA,FDA-2022-E-2225,Determination of Regulatory Review Period for Purposes of Patent Extension; SCEMBLIX,Notice,Determinations,2023-12-27T05:00:00Z,2023,12,2023-12-27T05:00:00Z,2024-06-25T03:59:59Z,2023-12-27T14:50:39Z,2023-28519,0,0,090000648635c3e9
FDA-2022-E-2225-0004,FDA,FDA-2022-E-2225,Letter from FDA CDER TO U.S. Patent and Trademark Office,Other,Letter(s),2023-12-01T05:00:00Z,2023,12,2023-12-01T05:00:00Z,,2023-12-01T20:49:17Z,,0,0,09000064862d4713
FDA-2022-E-2225-0003,FDA,FDA-2022-E-2225,Letter from FDA CDER to U S Patent and Trademark Office,Other,Letter(s),2023-01-10T05:00:00Z,2023,1,2023-01-10T05:00:00Z,,2023-01-10T17:33:25Z,,0,0,09000064855d38b7
FDA-2022-E-2225-0001,FDA,FDA-2022-E-2225,Patent Extension Application from Novartis AG,Other,Application,2022-09-14T04:00:00Z,2022,9,2022-09-14T04:00:00Z,,2022-09-14T15:29:06Z,,0,0,09000064852f7f99
FDA-2022-E-2225-0002,FDA,FDA-2022-E-2225,Cover Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2022-09-14T04:00:00Z,2022,9,2022-09-14T04:00:00Z,,2022-09-14T15:29:27Z,,0,0,09000064852f7f9c